Properties (64)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
other biotech firms
|
| gptkbp:advertising |
focus on unmet medical needs
expansion into new therapies |
| gptkbp:businessModel |
product development
strategic initiatives |
| gptkbp:CEO |
Michael_Gold
|
| gptkbp:clinicalTrials |
gptkb:Ocular_Therapeutix's_drug_delivery_system
ongoing Phase 3 pain management published biopharmaceutical company multiple sites ocular diseases inflammation management |
| gptkbp:collaborations |
universities
academic institutions hospitals and clinics |
| gptkbp:community_engagement |
healthcare_initiatives
|
| gptkbp:competitors |
ongoing analysis
|
| gptkbp:employeeCount |
growing
|
| gptkbp:enrollment |
varied demographics
|
| gptkbp:feedback |
positive results
|
| gptkbp:financialPerformance |
publicly reported
|
| gptkbp:focus |
ophthalmic therapeutics
|
| gptkbp:founded |
2014
|
| gptkbp:funding |
grants and investments
|
| gptkbp:future_plans |
expand product line
|
| gptkbp:goal |
improve patient compliance
|
| gptkbp:headquarters |
gptkb:Bedford,_Massachusetts
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ocular Therapeutix
|
| gptkbp:investmentFocus |
venture capital
institutional investors active communication |
| gptkbp:leadership |
experienced management team
|
| gptkbp:localBusiness |
public company
|
| gptkbp:market |
varies
ophthalmology |
| gptkbp:partnerships |
various pharmaceutical companies
research collaborations |
| gptkbp:patentCitation |
patents
|
| gptkbp:patentType |
Dextenza
|
| gptkbp:platforms |
drug delivery systems
|
| gptkbp:productLine |
diverse offerings
|
| gptkbp:products |
gptkb:Ocular_Therapeutix's_punctal_plug
gptkb:Ocular_Therapeutix's_drug_delivery_system Dextenza sustained-release implants unique delivery mechanism |
| gptkbp:regulatoryBody |
gptkb:FDA
|
| gptkbp:regulatoryCompliance |
ongoing
|
| gptkbp:research_areas |
new treatment options
dry eye disease post-surgical inflammation |
| gptkbp:research_focus |
sustained-release drug delivery
|
| gptkbp:specialties |
ophthalmic specialists
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:supplyChain |
managed effectively
|
| gptkbp:supportRole |
experts in ophthalmology
|
| gptkbp:targetMarket |
new regions
Dextenza |
| gptkbp:technology |
hydrogel_technology
|
| gptkbp:tributaryOf |
multiple drug candidates
|